- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00068055
IVIG - West Nile Encephalitis: Safety and Efficacy
A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (OMR-IGG-AM) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N4N
- University of Calgary
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0W3
- University of Manitoba
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-2050
- University of Alabama at Birmingham
-
Mobile, Alabama, United States, 36617
- University of South Alabama Medical Center
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic Hospital
-
Phoenix, Arizona, United States, 85013
- St. Joseph's Hospital and Medical Center
-
Tucson, Arizona, United States, 85724
- University of Arizona Health Sciences Center
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas
-
-
California
-
Chico, California, United States, 95926
- Enloe Medical Center
-
Daly City, California, United States, 94015
- Seton Medical Center
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
Harbor City, California, United States, 90710
- Kaiser Permanente South Bay Medical Center
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Orange, California, United States, 92868-3298
- University of California Irvine
-
Sacramento, California, United States, 95817
- University of California Davis Medical Center
-
San Francisco, California, United States, 94115
- California Pacific Medical Center
-
San Francisco, California, United States, 94114
- University of California San Francisco
-
Santa Rosa, California, United States, 95403
- Santa Rosa Kaiser Medical
-
-
Colorado
-
Denver, Colorado, United States, 80262
- University of Colorado
-
Denver, Colorado, United States, 80218
- Exempla St. Joseph Hospital
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- George Washington University Medical Center
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Idaho Falls Infectious Diseases, PLLC
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Loyola University
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5124
- Indiana University
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
Wichita, Kansas, United States, 67214
- Via Christi Regional Medical Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0084
- University of Kentucky
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
Bethesda, Maryland, United States, 20892-1662
- National Institutes of Health
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- University of Michigan
-
Detroit, Michigan, United States, 48201
- Wayne State University
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110-1093
- Washington University in St. Louis
-
St. Louis, Missouri, United States, 63110
- Saint Louis University
-
-
Montana
-
Butte, Montana, United States, 59701
- Mercury Street Medical Group
-
Missoula, Montana, United States, 59802
- Infectious Disease Specialists, PC
-
-
Nebraska
-
Broken Bow, Nebraska, United States, 68822
- Central Nebraska Medical Clinic
-
McCook, Nebraska, United States, 69001
- McCook Clinic, PC
-
North Platte, Nebraska, United States, 69101
- Great Plains Regional Medical Center
-
Omaha, Nebraska, United States, 68131
- Creighton University
-
Omaha, Nebraska, United States, 68105
- VA Medical Center - Omaha
-
Omaha, Nebraska, United States, 68198-7630
- University of Nebraska Medical Center
-
-
New Jersey
-
Belleville, New Jersey, United States, 07109
- Clara Maass Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- University of New Mexico
-
-
New York
-
Flushing, New York, United States, 11355
- Flushing Hospital Medical Center
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58506
- St. Alexius Medical Center
-
Fargo, North Dakota, United States, 58103
- Dakota Clinic at Innovis
-
Fargo, North Dakota, United States, 58122
- Meritcare Hospital
-
Minot, North Dakota, United States, 58701
- Trinity Health - Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University Hospital
-
Cleveland, Ohio, United States, 44106
- University Hospitals of Cleveland
-
Toledo, Ohio, United States, 43614
- University of Toledo
-
Wright-Patterson AFB, Ohio, United States, 45433
- Wright-Patterson Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Legacy Good Samaritan
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Lehigh Valley Hospital
-
West Reading, Pennsylvania, United States, 19611
- The Reading Hospital and Medical Center
-
-
Rhode Island
-
Pawtucket, Rhode Island, United States, 02860
- Memorial Hospital of RI
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Infectious Disease Consultations - Rapid City
-
Sioux Falls, South Dakota, United States, 57105
- Avera Research Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- Vanderbilt University
-
-
Texas
-
Dallas, Texas, United States, 75390-8884
- The University of Texas Southwestern Medical Center
-
Galveston, Texas, United States, 77555-0167
- The University of Texas Medical Branch
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
San Antonio, Texas, United States, 78229-3900
- The University of Texas Health Science Center
-
San Antonio, Texas, United States, 78236
- Wilford Hall Medical Center
-
Tyler, Texas, United States, 75708
- The University of Texas Health Science Center at Tyler
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
In order to participate in this clinical trial, all subjects (or legal representative) must provide written informed consent. Only patients meeting entry criteria will be enrolled. Eligible subjects must fall into one of two categories:
A. Hospitalized patients greater than or equal to 18 years of age with encephalitis and/or myelitis as defined below:
New neurologic abnormality:
- Asymmetric extremity weakness without sensory abnormality; or
- Other neurologic abnormality (including altered level of consciousness, dysarthria and dysphagia) plus fever (subjective or objective) within the previous 4 days AND
CSF examination within the previous 96 hours showing:
- Absence of organism on gram or fungal stain
- White blood cell count greater than or equal to 4 per cubic mm corrected for significant red blood cell contamination.
- Ratio of CSF: plasma glucose of greater than or equal to 40% (CSF glucose / plasma glucose greater than or equal to 0.4) Serum and CSF glucose levels should be obtained within 8 hours of each other for this calculation.
OR
B. Hospitalized patients, without encephalitis and/or myelitis as defined below, who meet the following criteria:
A positive IgM serology or PCR test for WNV in blood or cerebrospinal fluid, AND
Clinical illness compatible with WNV infection as described by occurrence of greater than or equal to 3 of the following findings during the preceding less than or equal to 10 days:
- Diarrhea
- Headache
- Fever > 38º C
- Nausea and/or vomiting
- Myalgias and/or arthralgias
- Nuchal rigidity
- Macular or papular rash
- New neurological abnormality AND
A risk factor for the development of WNV neurologic disease as defined by:
- Age greater than or equal to 40 years, or
- Age greater than or equal to 18 years plus immunosuppression, as defined by any of the following:
Hematologic malignancy; previous diagnosis of diabetes mellitus; chemotherapy within previous 4 weeks; stem cell transplant recipient or solid organ transplant recipient; taking immunosuppressive medications, including prednisone greater than or equal to 7.5 mg/day within the previous 4 weeks; history of human immunodeficiency virus (HIV) infection, congenital immunodeficiency syndrome (including common variable immunodeficiency)
Exclusion Criteria:
Unable to obtain valid informed consent History of intolerance (including anaphylaxis) to IVIg or related compounds Known history of IgA deficiency Known history of hypersensitivity to maltose
History of (or at time of study entry) hyperviscosity syndrome, such as but not limited to:
- Waldenstrom's macroglobulinemia
- Multiple myeloma
- Total white blood cell count > 80,000/cubic mm
- Hematocrit > 55%
- Platelet count > 700,000/cubic mm Meets criteria of Class III or IV of the New York Heart Association Classification for congestive heart failure patients Serum creatinine > 2.5 mg/dL or requires dialysis Alternate explanation (as determined by the investigator) for clinical findings (such as structural brain lesion, cerebrovascular accident, or other infectious disease, including confirmed infections with other flaviviruses) Pregnant or breastfeeding (negative serum or urine pregnancy test within previous 72 hours if woman is not postmenopausal or has not been surgically sterilized) Investigator's opinion that patient would be unable to adhere to protocol requirements Receipt of ribavirin, interferon alpha, intravenous immunoglobulin, or any investigational drug for treatment of WNV or hepatitis within 15 days prior to study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
60 subjects to receive Omr-IgG-am.
|
Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection.
This product is licensed in Israel, but not in the US.
|
ACTIVE_COMPARATOR: 2
20 subjects to receive Polygam® S/D (IVIG).
|
Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma.
When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
|
PLACEBO_COMPARATOR: 3
20 subjects to receive normal saline.
|
Normal Saline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety (including all causes of mortality) in the test IVIg (Omr-IgG-am™) group versus the 2 placebo groups, as defined by the total number of serious adverse events regardless of relatedness to study drug administration.
Time Frame: Duration of study.
|
Duration of study.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics of specific anti-WNV antibodies as measured by ELISA and PRNT methods.
Time Frame: Baseline (pre-dose) blood sample collected immediately prior to the beginning of the infusion. After the infusion, additional blood samples collected at 1 hr, 6 hr, 12 hr, 24 hr, 72 hr, and then at Day 5, Day 7, Day 14, Day 30, Day 60 and Day 90.
|
Baseline (pre-dose) blood sample collected immediately prior to the beginning of the infusion. After the infusion, additional blood samples collected at 1 hr, 6 hr, 12 hr, 24 hr, 72 hr, and then at Day 5, Day 7, Day 14, Day 30, Day 60 and Day 90.
|
Proportion of patients returning to pre-morbid baseline at 3 months, between treated and untreated groups of patients with WNV infection, as assessed by two scoring systems the Barthel Index and the MRS.
Time Frame: At 3 months.
|
At 3 months.
|
Improvement as compared to subject's own worst (of any earlier) evaluation, for each subject as defined by the combined results of the 4 neurological functional tests.
Time Frame: At 3 months.
|
At 3 months.
|
Mortality alone among confirmed WNV patients.
Time Frame: At 3 months.
|
At 3 months.
|
Combined morbidity and mortality in treatment versus placebo groups for all (including those without WNV infection) subjects by intention to treat analysis.
Time Frame: At 3 months.
|
At 3 months.
|
Combined primary endpoint of mortality and morbidity among confirmed WNV patients as assessed by four scoring systems: the Barthel Index, the MRS, the GOS and the 3MS, in the experimental treatment group versus the control group.
Time Frame: At 3 months.
|
At 3 months.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 03-107
- CASG 210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on West Nile Virus
-
Institute of Tropical Medicine, BelgiumUniversiteit Antwerpen; Victor Babes Hospital, Bucharest, RomaniaWithdrawnOxidative Stress | West Nile Virus | West Nile Fever | West Nile Fever Encephalitis | West Nile Fever Meningitis | West Nile Meningitis | West Nile Virus Meningoencephalitis | West Nile Fever Meningoencephalitis | West Nile Fever With Neurologic ManifestationRomania
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedWest Nile VirusUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Sarepta Therapeutics, Inc.CompletedWest Nile VirusUnited States
-
Leiden University Medical CenterUMC Utrecht; Erasmus Medical Center; Leiden University; Netherlands Institute of...Completed
-
Hawaii Biotech, Inc.Completed
-
National Institutes of Health Clinical Center (CC)CompletedEncephalitis | Myelitis | West Nile VirusUnited States
-
National Institutes of Health Clinical Center (CC)CompletedWest Nile VirusUnited States
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedEncephalitis | Meningitis | West Nile Virus Infection | West Nile Fever | West Nile Neuroinvasive Disease | Acute Flaccid Paralysis
-
National Institute of Allergy and Infectious Diseases...Completed
Clinical Trials on Omr-lgG-am
-
National Institutes of Health Clinical Center (CC)CompletedWest Nile VirusUnited States
-
FFF EnterprisesOMRIX BiopharmaceuticalsCompletedImmunologic Deficiency SyndromesUnited States, Canada
-
Istanbul University - Cerrahpasa (IUC)Not yet recruitingSleep Quality | Mother-Infant Interaction | AttachmentTurkey
-
Turku University HospitalMassachusetts General Hospital; University of TurkuUnknownBreastfeeding | Premature; Infant, Light-for-datesFinland
-
Washington University School of MedicineTerminatedGastrointestinal NeoplasmsUnited States
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingAutism Spectrum Disorder | Gastrointestinal SymptomsUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingHealthy | Overweight and ObesityUnited States
-
University of RoehamptonCompleted
-
AllerganCompletedBlue Light DamageUnited States
-
Auris Medical AGCompleted